Trials / Conditions / BRAF Gene Mutation

BRAF Gene Mutation

17 registered clinical trials studyying BRAF Gene Mutation — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M NCT06287463	Deciphera Pharmaceuticals, LLC	Phase 1
Recruiting	Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer NCT06449989	Blokhin's Russian Cancer Research Center	—
Terminated	Study of IK-595 in RAS- or RAF-altered Advanced Tumors NCT06270082	Ikena Oncology	Phase 1
Recruiting	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924	Institut de Recherches Internationales Servier	Phase 1 / Phase 2
Recruiting	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma NCT04903119	Rina Plattner	Phase 1
Terminated	Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations NCT04488003	BioMed Valley Discoveries, Inc	Phase 2
Active Not Recruiting	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer NCT04238624	Memorial Sloan Kettering Cancer Center	Phase 2
Withdrawn	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma NCT03972046	TriHealth Inc.	Phase 2
Completed	Continued Access to RXDX-105 NCT03784378	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - NCT03750175	Karen-Lise Garm Spindler	—
Completed	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma NCT02367859	Stanford University	Phase 2
Unknown	Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma NCT03088176	West Cancer Center	Phase 1
Completed	Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618	University of Southern California	Phase 2
Terminated	Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction NCT01907802	National Cancer Institute (NCI)	Phase 1
Completed	French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings NCT01700582	Intergroupe Francophone de Cancerologie Thoracique	—
Completed	Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mu NCT01531361	M.D. Anderson Cancer Center	Phase 1
Available	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies NCT04566393	xCures	—